Does continuous renal replacement therapy cause coagulopathy?

Does CRRT Cause Coagulopathy?

CRRT itself does not directly cause coagulopathy; rather, it can induce dilutional coagulopathy through circuit priming and blood product consumption, while the underlying critical illness and anticoagulation strategies used during CRRT are the primary drivers of coagulation abnormalities.

Understanding the Coagulation Effects

The relationship between CRRT and coagulation is complex and bidirectional:

Dilutional Effects

CRRT can cause dilutional coagulopathy, particularly during circuit initiation and exchanges. When circuits are primed with crystalloid or blood products, the patient's coagulation factors and platelets become diluted 1. This is especially problematic in low-birth-weight neonates and small patients where the circuit volume represents a significant proportion of total blood volume. One case demonstrated marked thrombocytopenia (platelets dropping from 305,000 to 59,000/μL) and severe coagulopathy (PT/INR >10) following CRRT initiation with red cell concentration-primed circuits 1.

Procoagulant Activity During CRRT

Paradoxically, CRRT actually induces procoagulant activity rather than bleeding tendency in most patients. Thromboelastography studies show significant changes in coagulation initiation parameters (R, K, alpha angle) during CRRT, with the maximum procoagulant changes occurring around 24 hours after procedure initiation 2. This procoagulant state can lead to circuit clotting, which is why anticoagulation is typically required.

The Real Culprits

The coagulation abnormalities attributed to CRRT are primarily due to:

1. Anticoagulation strategies: The choice and dosing of anticoagulants (heparin, citrate, or none) directly affect coagulation status 3, 4

2. Underlying critical illness: Conditions like sepsis, COVID-19, and acute kidney injury create hypercoagulable states that manifest during CRRT 5

3. Uremic platelet dysfunction: The uremic state itself causes hemostatic defects that are typically reversible with adequate renal replacement therapy 6

Clinical Management Approach

Anticoagulation Selection

Regional citrate anticoagulation is recommended for continuous RRT in patients without contraindications 4. The 2020 KDIGO guidelines support this approach based on existing data.

For patients at high bleeding risk:

• CRRT can be performed successfully without anticoagulation, though circuit life may be less than 24 hours 3
• Avoid systemic anticoagulation with heparin or direct thrombin inhibitors in high-bleeding-risk patients 3

Monitoring Requirements

When anticoagulation is used, safety monitoring is essential 3:

For heparin anticoagulation:

• Measure activated clotting times (ACT) or systemic PTT
• Monitor platelet counts routinely for heparin-induced thrombocytopenia

For citrate anticoagulation:

• Frequent measurements of post-filter and serum-ionized calcium to titrate citrate and calcium replacement 3
• Monitor systemic acid-base balance in patients at high risk for citrate accumulation

Minimizing Dilutional Coagulopathy

In vulnerable populations (neonates, small patients):

• Consider priming new circuits with blood from the current circuit during exchanges to minimize dilutional effects 1
• Anticipate and prepare for platelet and fresh frozen plasma transfusions during initial CRRT setup

Key Pitfalls to Avoid

1. Don't assume CRRT causes bleeding: The procoagulant activity during CRRT means circuit clotting is often more problematic than bleeding 2

2. Don't overlook hypercoagulability: Conditions like COVID-19 substantially increase extracorporeal coagulation risk during CRRT 5. Increase anticoagulation dosing accordingly.

3. Don't use one-size-fits-all anticoagulation: Tailor anticoagulation based on bleeding risk, coagulation status, drug metabolism characteristics, and treatment needs 7

4. Don't forget the circuit volume: In small patients, the extracorporeal circuit volume can cause significant dilutional effects requiring proactive blood product support 1